Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert J KreitmanIra Pastan

Abstract

To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL). Eligible patients had relapsed/refractory HCL after ≥ two prior therapies and required treatment because of abnormal blood counts. Patients received moxetumomab pasudotox 5 to 50 μg/kg every other day for three doses (QOD ×3), with up to 16 cycles repeating at ≥ 4-week intervals if patients did not experience disease progression or develop neutralizing antibodies. Twenty-eight patients were enrolled, including three patients each at 5, 10, 20, and 30 μg/kg, four patients at 40 μg/kg, and 12 patients at 50 μg/kg QOD ×3 for one to 16 cycles each (median, four cycles). Dose-limiting toxicity was not observed. Two patients had transient laboratory abnormalities consistent with grade 2 hemolytic uremic syndrome with peak creatinine of 1.53 to 1.66 mg/dL and platelet nadir of 106,000 to 120,000/μL. Drug-related toxicities in 25% to 64% of the 28 patients included (in decreasing frequency) grade 1 to 2 hypoalbuminemia, aminotransferase elevations, edema, headache, hypotension, nausea, and fatigue. Of 26 patients evaluable for immunogenicity, 10 p...Continue Reading

References

Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J KreitmanI Pastan
Jul 28, 2001·The New England Journal of Medicine·R J KreitmanI Pastan
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grant R GoodmanAlan Saven
Aug 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J KreitmanIra Pastan
Sep 23, 2006·Hematology/oncology Clinics of North America·Michael R Grever
Sep 23, 2006·Hematology/oncology Clinics of North America·Adi Gidron, Martin S Tallman
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raffit HassanIra Pastan
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ralph F AldersonIra Pastan
May 6, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J KreitmanIra Pastan
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J KreitmanIra Pastan
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael R Grever, Gerard Lozanski
Aug 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John A Blake-HaskinsRobert J Kreitman

❮ Previous
Next ❯

Citations

Sep 4, 2012·Cancer Immunology, Immunotherapy : CII·Ahmad TradJoachim Grötzinger
Jul 31, 2013·Current Hematologic Malignancy Reports·Robert J Kreitman
May 23, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Loretta Sullivan-ChangJoseph M Tuscano
Jul 4, 2012·Proceedings of the National Academy of Sciences of the United States of America·Wenhai LiuIra Pastan
Dec 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ronit MazorIra Pastan
Oct 13, 2012·Journal of Hematology & Oncology·Shundong CangDelong Liu
Jul 4, 2012·International Journal of Molecular Sciences·Carmela Dantas-BarbosaAndrea Queiroz Maranhao
Aug 24, 2013·Toxins·Antonella Antignani, David Fitzgerald
Feb 18, 2014·Blood Cancer Journal·V MaevisI G H Schmidt-Wolf
Apr 24, 2014·Future Oncology·Manjari Pandey, Daruka Mahadevan
Jun 14, 2014·Blood Cancer Journal·M StaudingerM Peipp
Mar 22, 2014·Current Treatment Options in Oncology·Preetesh JainFarhad Ravandi
May 21, 2014·Proceedings of the National Academy of Sciences of the United States of America·Chris KingDavid Baker
May 7, 2014·Proceedings of the National Academy of Sciences of the United States of America·Ronit MazorIra Pastan
Sep 18, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Thomas SchirrmannStefan Barth
Aug 26, 2014·Future Oncology·Christian M CapitiniPaul M Sondel
Oct 1, 2014·Nature Reviews. Clinical Oncology·Brandon G SmagloLouis M Weiner
Jun 7, 2015·Drug Discovery Today·Jayaprakasam MadhumathiRama S Verma
Jan 8, 2015·Leukemia & Lymphoma·Preetesh JainFarhad Ravandi
Sep 4, 2015·Expert Opinion on Investigational Drugs·Tadeusz RobakPawel Robak
Dec 15, 2015·Expert Opinion on Drug Delivery·Sagun ParakhAndrew M Scott
Apr 9, 2014·Expert Opinion on Investigational Drugs·Tadeusz Robak, Ewa Robak
Apr 26, 2015·Expert Opinion on Drug Discovery·Kobra Omidfar, Maryam Daneshpour
Jan 15, 2013·Journal of Drug Targeting·Jie SongZengshan Liu
Jun 2, 2012·Expert Opinion on Biological Therapy·David M Goldenberg, Robert M Sharkey
Feb 13, 2016·Immunological Reviews·Ronit MazorIra Pastan
Aug 12, 2014·Blood Reviews·Michael R GreverLeslie A Andritsos
Jul 4, 2012·Pharmacology & Therapeutics·Takumi KiwamotoBruce S Bochner
Sep 1, 2015·Critical Reviews in Oncology/hematology·Esmeralda Chi-Yuan TeoColin Phipps
Nov 29, 2015·Best Practice & Research. Clinical Haematology·Leslie A Andritsos, Michael R Grever
Nov 29, 2015·Best Practice & Research. Clinical Haematology·Estella MatutesElias Campo
Nov 29, 2015·Best Practice & Research. Clinical Haematology·Bartlomiej M GettaMartin S Tallman
Feb 25, 2015·Journal of Clinical Pharmacology·Dalal AlDeghaitherLouis M Weiner
Dec 11, 2013·British Journal of Haematology·Robin E GasiorowskiDerek N J Hart
Nov 29, 2015·Best Practice & Research. Clinical Haematology·Robert J Kreitman, Ira Pastan
Nov 2, 2015·Leukemia Research·Evgeny AronsRobert J Kreitman
Aug 1, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael A Pulsipher
Mar 3, 2015·Pediatric Blood & Cancer·Nirali N ShahAlan S Wayne

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert J KreitmanIra Pastan
Proceedings of the National Academy of Sciences of the United States of America
Masanori OndaIra Pastan
© 2022 Meta ULC. All rights reserved